Tips for respiratory virus testing

Tips for respiratory virus testing

In New Zealand and Australia, the activity of acute respiratory diseases is at a higher level than usual for this time of year because of rhinoviruses and SARS-CoV-2, according to recent health department data. If a patient has a fever and cough and feels exhausted, it could be COVID-19 and it could also be one of the new variants of Sars-CoV- 2. Equally if not more so It’s important to consider if its  Influenza A  or B and RSV Respiratory Synctovirus. Inscience has the simple and much admired Biopen that combines all of these significant all year round respiratory virus in one easy to use Biopen rapid test. What significance do rapid tests have? When should doctors advise or should people consider testing?

When to Test

People at a higher risk for severe COVID-19 get the most benefit from tests and knowing what they are dealing with. This population includes the following groups:

  • Older people
  • Early childhood and school children
  • Immunocompromised people
  • People with respiratory diseases
  • People with cardiovascular diseases
  • People with liver and kidney diseases
  • People with neurological diseases
  • People with obesity

If testing detect SARS-CoV-2 infection early, people can receive antivirals such as Paxlovid, for example, to reduce morbidity and mortality risks. IMPORTANTLY , people without specific risks should test themselves if they plan to visit vulnerable individuals.

Detecting New Variants

A recent  comprehensive study  provides evidence that antigen tests targeting the nucleocapsid (N) protein of SARS-CoV-2 also detect new variants. The Biopen is proven to detect the new and current variants.

Test Timing

Is the time of day you test significant. There is uncertainty about what time of day to test but such effects can be mitigated by performing multiple COVID-19 rapid tests over time. The US Food and Drug Administration (FDA) and similar organizations make this recommendation. Studies of symptomatic individuals show that serial tests increase accurate diagnosis. This means a series of tests conducted following known exposure and continued while symptoms continue to exist

In the early stages of infection, swabs collected may contain too little virus material because of widespread immunity against SARS-CoV-2 present resulting from previous infections or vaccination. This false negative is significant in asymptomatic individuals or people in the incubation phase; a single test may in those without strong symptoms, or those recently exposed, have a false negative result. Therefore, the FDA recommends conducting at least two additional tests 48 hours apart in case of a negative test result.

Costs of Rapid Tests

The days of free tests are long gone.

Test kits are available from Inscience or in some pharmacies and supermarkets. In boxes of 20 tests is the most economical with lots of 5 or 10 also sold costing between $6 and S15(4 respiratory virus in one test) each, depending on the provider. If a person still has old rapid coronavirus tests in his or her medicine cabinet, are they still suitable?

Expired Tests

Properly stored tests that have not passed their expiration dates can still be used. But microbiologist and pathologist Dr Daniel Rhoads from the Cleveland Clinic in Ohio warns against expired rapid tests.

The chemicals may have decomposed, the solvent may have evaporated, or antibodies may have lost their effectiveness, thus making false negative results more likely. “These are proteins that can decompose over time,” said Rhoads.

ADHD, medications and workplace drug testing programmes

ADHD, medications and workplace drug testing programmes

ADHD, medications and workplace drug testing programmes

ADHD affects around one in twenty New Zealanders and the number of people diagnosed with the disorder is on the rise. In recent years in particular, there has been a steep increase in the number of adults diagnosed with ADHD. But what’s this got to do with workplace drug testing?

Brief information on ADHD

ADHD, or Attention Hyperactivity Disorder, is a complex neuro-developmental disorder characterised by patterns of inattentive, impulsive and sometimes hyperactive behaviour. Often, people with ADHD also face emotional regulation challenges.

These behaviours stem from underlying neurological differences. Without intervention, ADHD can lead to significant functional disability across all areas of life. However, with evidence-based treatment and support, individuals with ADHD can learn to manage challenges, embrace strengths and lead fulfilling lives.

This support can include medication. There has been a lot of media attention in recent years on the significant rise in ADHD sufferers being prescribed medication. In a recent news article published a few months ago, it was claimed that the number of Australians being prescribed ADHD medication has doubled in five years.

What’s the link between ADHD and workplace drug testing?

While there are many medicines and combinations of medicines that can be prescribed for ADHD, often a stimulant medicine is part of the mix. Stimulants used in treatment of ADHD help improve behaviour, attention and memory in ADHD by adjusting chemical messengers in the brain.

While there are different stimulants that can be prescribed for ADHD, some are what can be described in layman terms as amphetamine-like. The most common ADHD medications are Dex Amphetamine, Adderall, Concerta and Ritalin. The latter is the most common ADHD medicine prescribed.

The fact that these medications are essentially amphetamines (low dose)is a critical aspect. It’s why some people on ADHD medication may provide a not-negative test during workplace drug testing. A not-negative is more likely if the dose was very recent or is a medium to high dose

While the drugs that can be detected by testing can vary, depending on the workplace drug testing provider and the Workplace, those testing to AS/NZS Standards routinely check for amphetamines. That’s because, while amphetamines can be prescribed for various medical conditions, including ADHD, it can also be an abused drug taken illegally in higher quantities for recreational purposes.

An example is an illicit amphetamine is one commonly called speed. Speed and other amphetamine type substances are generally considered as a psychoactive substance that gives user feelings of happiness, confidence and energy. It can also lead to an increase in heartbeat and breathing, fits, passing out, paranoia, mood swings, hallucinations, confusion and more, which is why it has no place in a workplace where safety is important.

It should be highlighted that when taken as prescribed, amphetamine-like medication is largely safe and medically indicated. While side effects can occur, for most people on long-term prescribed use, the medication has proven to be safe and effective and if it is taken according to the prescriptions, are safe to work and drive a vehicle.

Medications with risk and side effects are not just for those treated for ADHD

While ADHD medication is increasingly being prescribed, it is one only of the prescribed medications that can lead to not-negative workplace drug testing results. It is not the only legally prescribed medication that triggers a not-negative result and needs sensitive, safety-focused responses in the workplace. It’s important to understand that prescribed drugs can lead to being unsafe at work and have functions similar to many illegal drugs. Workplace drug testing is not designed only to detect illicit drugs but to detect substances with the potential to be a safety issue. Taking a medication prescribed for another is illegal.

So, what drugs that are medications can lead to the person taking the medication being unsafe to drive or work in safety-focused roles, even when the drug is taken as directed? Examples can include codeine, morphine and fentanyl, all opioids, which belong to the same drug family as heroin. Opiates are widely prescribed and used and present considerable risks such as tolerance, dependence, addiction, low oxygen levels due to suppressed breathing response, fainting, dizziness, sedation and more. Another example that is very topical of late is medicinal cannabis.

While most doctors should and do discuss side effects with their patients, you must remind workers that there is a responsibility on them to explore the potential side effects when taking prescribed medication, particularly if they work in a job where workplace drug testing is carried out and if they plan to operate a vehicle privately or for work. Questioning a doctor about side effects, telling the doctor about what your work hazards and whether a drug could affect their ability to drive or work should always be part of the conversation.

Could someone face consequences for failing workplace drug testing while on medication?

What happens when someone’s ADHD or other medication is detected in workplace drug testing? Could someone – perhaps wrongly – lose their job or face significant consequences?

In general the answer is no.

Initial testing (an onsite drug screen), which may produce a not-negative test for amphetamines, should always be followed by confirmation testing, using a method that identifies the exact substance o drug compound and not just the family or class of substances. This confirmed laboratory test is a more accurate and definitive, independent laboratory analysis. This testing will be able to distinguish between the different forms of amphetamines taken and is the only test result on which a workplace should exercise any employment consequences.

An initial not-negative result does not mean that illicit substances, medication or sometimes even a substance that is a safety risk is the reason for that result. Prescription medications can trigger a not-negative result as we have highlighted earlier and the laboratory report is essential however it can only tell you if the medication is consistent with the substance declared or if it was taken or declared to mask the use of an illicit drug.

The confirmed Lab result will tell you whether the medication declared has caused the result, but not that it is legally prescribed for and to the worker and is being used as directed.

What is needed next if a prescribed medication detected in a routine drug test has been confirmed? Even if the medication is identified and proven to be prescribed to that person, especially in the case of a worker claiming prescribed Cannabis(THC), how do you know if you should be concerned about the potential for it to affect workplace safety or what other actions for Health and safety you may need to take?

The workplace can request proof of a legal prescription and legally dispensed medication (the packet or bottle of medication) to the worker, but an MRO is able to work better within the medical privacy boundary to provide the workplace with support to better understand workplace risk and, in most cases, can report on fitness to work specific to the worker, medication, and workplace risk.

A Medical Review Officer (MRO) can provide advice on whether the medication is considered safe to take for the worker, taking into account the job role, and the medical condition the medication is treating. Furthermore, the MRO can also verify a legitimate test process and positive result relevant to safety, determine if the drug test is consistent with the declared medication dose and give you the support to apply the tools you have to manage the individual via your company’s drug and alcohol policy.

If you are a worker who is on ADHD medication that is amphetamine-like, or in fact, any of the medications that may cause safety concerns, i.e. Opiates for pain or antianxiety meds with the potential to affect your performance and your workplace carries out drug testing, it’s a good idea to explore this with your doctor and let your employer know immediately. It is the smart and responsible thing to do to be proactive rather than having to explain a not-negative result after the fact or, more importantly, to place yourself and others at unnecessary risk.

For workplaces, there are also some key messages:

  • Firstly, it’s important to include detailed information and advice about prescribed medication, including ADHD medication, in your workplace drug and alcohol management policy and the responsibility to report it.
  • Educate your workforce on the risks of coming to work after taking certain types of prescription drugs. Some medications may only present risk in the first week of use or for increased dosage.
  • Reiterate to your workforce that the aim of managing certain prescription drugs properly is to ensure workplace safety.
  • Encourage your workforce to report to their manager or supervisor immediately if they have been prescribed medication that could make them unsafe to work or could potentially lead to a not-negative drug test.
  • Implement random workplace drug testing to raise awareness of the policy and improve early identification and workplace safety. Drug and alcohol testing is the only sure way to know if someone may be under the influence of a drug or alcohol and is unsafe to be in the workplace.

By Ann-louise Anderson, Inscience Limited

DC 3000 by Draeger

DC 3000 by Draeger

DC 3000 – Introducing the Draeger DrugCheck (DC) 3000 from Inscience

Are you looking for a cutting-edge solution to ensure safety and compliance in your workplace? Look no further than the Draeger DrugCheck 3000.

Inscience are the premium NZ distributor of this unique drug screening device which sets the gold standard for accuracy, reliability, and ease of use in any non instrument supported saliva drug test . Whether employed by a law enforcement officer, a healthcare professional, third party service provider or a workplace/employer, the DrugCheck 3000 is designed to meet your needs and exceed your expectations.

DC 3000

DC 3000 key features:

Z

Accuracy you can trust:

The DrugCheck 3000 utilizes Draegers advanced impairment check technology to detect the AS/NZS4760:2019 panel of most commonly used drugs with potential to impair which includes marijuana(THC), cocaine, methamphetamine, amphetamines and opiates. With its high sensitivity and specificity, which translates to less cost from false positives, you can rely on its results with confidence.

Z

Rapid results:

In just minutes, the DrugCheck 3000 is the most rapid for specimen collection and time to result. It delivers accurate and actionable results, allowing you to make informed decisions for safety quickly.

Z

User-friendly design:

The DC 3000 device is designed with simplicity in mind. Its intuitive interface ensures ease of use, even for those without extensive technical expertise although all workplace related drug screening must be performed by a suitable(NZQA) qualified person.  See our training page to find out more.
Z

Portable and convenient:

Compact and lightweight, the DrugCheck 3000 is easy to carry and use in various settings. It’s ideal for on-the-go testing or as a reliable option in your workplace.
Z

Compliance assurance:

Stay in line with legal and regulatory requirements effortlessly. The Drugcheck 3000 is fully verified to AS/NZS4760:2019. The DrugCheck 3000 is designed to help you maintain a safe and drug-free environment.
Z

Support second to none:

Not only is the Draeger DC3000 supported with amazing technical support from Inscience as Draegers premium NZ distributor but you will have free access to a mobile/tablet APP lication that provides a “how to use video” with the app help for timing while recording everything you need in a report including interpretation of results on a form you can email as an encrypted report immediately from your device.

Trust in the Draeger DrugCheck 3000 to keep your workplace, whanau, community, and roads safe from the risks associated with impairing drugs and consider combining its use with Draegers range of certified AS3547:2019 breathalysers as used by NZ Police. Discover a new level of confidence in drug screening technology with the Draeger DrugCheck 3000 – your partner in safety and compliance.

Contact us on +64 (0)9 376 0121 today to learn more about how the DrugCheck 3000 can benefit your organization or operation, or order now.

Complications of Medicinal (THC) Cannabis- Part 1 of a series of 5 articles

Complications of Medicinal (THC) Cannabis- Part 1 of a series of 5 articles

The use of medicinal cannabis among adults in New Zealand is on the rise, leading to concerns about health impacts. Doctors are often reluctant to discuss the topic or inform patients about potential risks.

However, cannabis can have serious side effects, especially when combined with certain medications, and older adults may be more sensitive to its effects. It can interact negatively with drugs like warfarin and clobazam, leading to dangers such as internal bleeding. Doctors also need to be aware of their patients’ cannabis use before surgery, as anesthesia requirements may differ.

Lack of education on cannabis in medical school contributes to doctors’ hesitation in advising patients. While cannabis can provide relief for conditions like depression and anxiety, doctors should address underlying causes and consider work safety and drug tests. Educating doctors about cannabis during training would better equip them to support patients using it medicinally.

RSV here this winter with a vengeance

RSV here this winter with a vengeance

RSV here this winter with a vengeance

Before the COVID-19 pandemic in early 2020, most RSV seasons were pretty typical – A Flu/RSV season would start in the late Autumn with cases trickling in from mid- to late April, and then a peak in late July to mid-August. By the time spring rolled around in most temperate climates, you would see much less circulation of RSV.

This year in Europe and USA, we saw RSV come back with a vengeance and really start to tick up a lot earlier in their Autumn, peak later and last longer. A lot of people, especially children, presented in a very short time period and with much higher hospitalization rates in the northern winter than in the past.

It’s interesting because the COVID 19 pandemic and lockdowns disrupted the circulation of RSV and other common respiratory viruses and this none more so than during the extended lockdowns in NZ. So as we come into winter 2023, we expect a similar abnormal pattern as the Northern hemisphere and increased cases of RSV and other respiratory virus, as well as the Omicron variant Covid virus.

In short: by the time we get to this NZ winter 2023 it is anticipated we will see co-circulation of SARS-CoV-2 and flu during NZ winter time and at significantly higher than it has been in previous typical seasons.

What diagnostics do we have for RSV/ Flu/ Covid 19?

Before the pandemic, we often didn’t have to use a diagnostic test if it was the middle of Autumn /winter and an adult or child came in with wheezing and symptoms that were consistent with bronchiolitis. You could make that diagnosis on history and physical aspects alone. You knew it was RSV season, it was probably RSV causing that episode of bronchiolitis especially if a child in their first year of life. Then came Covid 19 and we added the COVID 19 RAT or PCR to our diagnostics. Now, because of the atypical season and circulation, reduced antibodies and immunity that we’ve been seeing, an accessible rapid diagnostic tool with flu/RSV and SARS-CoV-2 is a significant advantage to have. Is it wise or safe to have someone with cold/flu symptoms at work undiagnosed? How many people continue to work when their Covid-19 RAT is negative? With the Nasal pentest 4 in 1, we/you get to see four different very significant respiratory viruses with a single swab panel.

Vaccinate, diagnose and isolate are the three key elements to safety from respiratory virus in the workplace. Click the button below to find out how InScience can help you.

Vaccination for Influenza and Covid Winter 2023

Vaccination for Influenza and Covid Winter 2023

Vaccination for Covid (boosters) and the ‘flu vaccination can now be administered in one visit. Vaccination – love it or hate it – will assist in reducing the number of NZers getting these viruses and passing them on, will also reduce the severity of the ‘flu and or COVID which may otherwise require hospitilisation over our coming NZ winter.

I recently posted about a Swiss study which noted that “Vaccination still plays a significant role regarding the main outcome”, since a secondary analysis in this most recent study showed that unvaccinated COVID patients were twice as likely to die compared to ‘flu patients.

Vaccination for Influenza and Covid Winter 2023

“Our results demonstrate that COVID-19 still cannot simply be compared with influenza,” they wrote. While the death rate among COVID patients was significantly higher, there was no difference in the rate that COVID or ‘flu patients were admitted to the intensive care unit, which was around 8%.

Source
JAMA Network Open: “Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland.”